Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
Doriana Landi, Alfonso Grimaldi, Francesca Bovis, Marta Ponzano, Roberta Fantozzi, Fabio Buttari, Elisabetta Signoriello, Giacomo Lus, Matteo Lucchini, Massimiliano Mirabella, Maria Cellerino, Matilde Inglese, Gaia Cola, Carolina Gabri Nicoletti, Giorgia Mataluni, Diego Centonze, Girolama Alessandra Marfia
Abstract
BACKGROUND AND OBJECTIVES: To investigate the longitudinal dynamic of lymphocyte subsets during treatment with ocrelizumab (OCR) in patients with multiple sclerosis (PwMS). METHODS: , and natural killer) counts were analyzed at baseline, 6 months, and 12 months. Rate of lymphocytopenia for each subset was calculated at all time points in all groups. RESULTS: cells at the sixth month, and for total cells at the 12th month. DISCUSSION: OCR per se exerts a modest depleting effect on T cells that seems rather due to a carryover phenomenon of previous therapies, particularly FTY. These data may help in the overall evaluation of the risk/benefit profile of treatment sequencing.